Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1458046
This article is part of the Research Topic Exploring the Key Targets and Compounds That Manipulate Brain Neurocircuits Against Mental Disorders and Psychiatric Volume II View all 7 articles

Multi-Omics Profiling Reveals Peripheral Blood Biomarkers of Multiple Sclerosis: Implications for Diagnosis and Stratification

Provisionally accepted
Qinming Zhou Qinming Zhou 1Zuoquan Xie Zuoquan Xie 2Lu He Lu He 3Guangqiang Sun Guangqiang Sun 4*Huanyu Meng Huanyu Meng 1Zhiyu Luo Zhiyu Luo 4*Yuan Feng Yuan Feng 4*Xingkun Chu Xingkun Chu 4*Liang Li Liang Li 4*Jing Zhang Jing Zhang 4*Yong Hao Yong Hao 5*Meiyu Geng Meiyu Geng 2*Xiang Zhang Xiang Zhang 6*Sheng Chen Sheng Chen 1,7*
  • 1 Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
  • 2 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  • 3 Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 4 Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
  • 5 Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 6 Department of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
  • 7 Jiangsu Province Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Background: Multiple sclerosis (MS), a chronic autoimmune disorder marked by demyelination in the central nervous system, is exceptionally uncommon in China, and remains poorly understood in terms of its peripheral blood manifestations.We conducted a cohort study comprising 39 MS patients and 40 normal controls (NC). High-dimensional mass cytometry, protein arrays, and targeted metabolomics were utilized to profile immune subsets, proteins, and metabolites in blood. Differences in multi-omics signatures were scrutinized across varying MS subtypes.Results: Immune profiling demonstrated an elevation in various B cell subsets and monocytes, alongside a reduction in dendritic cells among MS patients. Proteomic data revealed a downregulation in neurotrophic and tissue repair proteins. Metabolomic assessment showed a noted decrease in antiinflammatory molecules and sphingolipids. Integrated analysis identified distinct molecular patterns distinguishing MS from controls. Additionally, multi-omics differences among different MS subtypes were uncovered. Notably, hippuric acid levels was consistently lower in MS subgroups with greater disease severity.This study represents the pioneeringfirst exploration of multi-omics in Chinese MS patients, presenting a comprehensive view of the peripheral blood changes in MS. Our study underscores the robust capability of multi-omics assessments in identifying peripheral blood biomarkers that delineate the varied clinical presentation, and facilitates future development of biomarkers and targeted therapeutic interventions in MS.

    Keywords: Multiple Sclerosis, multi-omics, blood immune phenotyping, proteomic, metabolomic, clinically isolated syndrome, secondary progressive MS

    Received: 01 Jul 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Zhou, Xie, He, Sun, Meng, Luo, Feng, Chu, Li, Zhang, Hao, Geng, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Guangqiang Sun, Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
    Zhiyu Luo, Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
    Yuan Feng, Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
    Xingkun Chu, Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
    Liang Li, Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
    Jing Zhang, Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China
    Yong Hao, Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 201805, China
    Meiyu Geng, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
    Xiang Zhang, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
    Sheng Chen, Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, Shanghai Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.